China Post-marketing Surveillance (PMS) Study of Aldurazyme®
Study of Investigational Medication for Chinese MPS I Participants
Study Overview
This is a single treatment arm study that is open-label to be conducted in Chinese participants with MPS I.
Trial Objectives are to evaluate the safety and tolerability of Aldurazyme in Chinese MPS I participants, and to evaluate the efficacy of Aldurazyme on the percent change of urinary glycosaminoglycans (uGAGs) from baseline to Week 26. The study will also evaluate the effect on uGAG level and liver volume (hepatomegaly) after 26 weeks, with Aldurazyme treatment in Chinese MPS I participants.
Treatment duration will include: 2 weeks of screening, 26 weeks of treatment and 1 week of follow-up period. During the treatment period, weekly visits are designed to accommodate weekly administration of Aldurazyme (laronidase).
Study Details
Study duration for each participant will be a total of 29 weeks which will include 2 weeks of screening, 26 weeks of treatment period and 1 week of follow-up period.
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
- Conditions: Mucopolysaccharidosis I
-
Age: 5 years or above
-
Gender: All
Inclusion Criteria:
- Chinese participants have a documented diagnosis of MPS I confirmed by measurable clinical signs and symptoms of MPS I and fibroblast or leukocyte IDUA (iduronidase) activity <10% of normal.
- Participants have to be able to stand independently and walk a minimum of 5 meters in 6 minutes.
- A female participant is eligible to participate if she is not pregnant or
breastfeeding, and at least one of the following conditions applies:
- Is not a woman of childbearing potential (WOCBP).
- OR
- Is a WOCBP and agrees to use an acceptable contraceptive method during the intervention period and at a minimum until 7 days after the last dose of study intervention.
- A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within the screening period before the first dose of study intervention.
- If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
- Contraceptive/barrier method is not applicable for male participants.
Exclusion Criteria:
- Prior tracheostomy or bone marrow transplantation or hematopoietic stem cell transplantation.
- Have a plan to undergo bone marrow transplantation or hematopoietic stem cell transplantation within half a year after enrollment.
- Received an investigational drug, or device, other than Aldurazyme, within 30 days prior to study enrollment.
- Received an investigational gene therapy.
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
This study investigates the safety and effectiveness of an investigational medication in treating MPS I. The purpose of this study is to evaluate changes in urinary glycosaminoglycans (uGAGs) and liver size in participants over a 26-week period.
Participants will receive weekly treatments of the investigational medication for 26 weeks. The study includes an initial screening period and a follow-up after the treatment phase. Participants will be monitored for changes in uGAG levels and liver volume, which are indicators of the disease's progression.
- Who can participate: Eligible participants are Chinese individuals diagnosed with MPS I, who can stand independently and walk at least 5 meters in 6 minutes. Female participants must not be pregnant or breastfeeding and should agree to use contraception if of childbearing potential.
- Study details: Participants will receive weekly doses of the investigational medication over 26 weeks. The study will monitor changes in disease markers, such as uGAG levels, to assess the treatment's impact.
- Study timelines and visits: The study will last 29 weeks. The study requires 29 visits.
